Directed new share issue in Clavis Pharma ASA (NO) — NOK 154 million

Carnegie acted as joint lead manager and joint book-runner in the directed new share issue of 4.4 million shares at a subscription price of NOK 35.00 per share. Clavis Pharma ASA is a clinical stage oncology discovery and drug development company, with a portfolio of novel anti-cancer drugs in development.November, 2010.